NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study

Wenying Fan; Muneeswar Gupta Nittala; Charles C. Wykoff; David M. Brown; Akihito Uji; Jano van Hemert; Alan Fleming; Gavin Robertson; Srinivas R. Sadda; Michael Ip

doi:10.1097/IAE.0000000000003358

NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study

Wenying Fan, Muneeswar Gupta Nittala, Charles C. Wykoff, David M. Brown, Akihito Uji, Jano van Hemert, Alan Fleming, Gavin Robertson, Srinivas R. Sadda, Michael Ip

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection.

METHODS: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically.

RESULTS: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm2 (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm2 (P = 0.004).

CONCLUSION: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.

Original language	English (US)
Pages (from-to)	426-433
Number of pages	8
Journal	Retina
Volume	42
Issue number	3
DOIs	https://doi.org/10.1097/IAE.0000000000003358
State	Published - Mar 1 2022

Keywords

Diabetic retinopathy
Retinal vascular bed area
Ultrawide field
Vascular endothelial growth factor
Receptors, Vascular Endothelial Growth Factor/therapeutic use
Prospective Studies
Intravitreal Injections
Humans
Middle Aged
Retinal Vessels/pathology
Male
Recombinant Fusion Proteins/therapeutic use
Angiogenesis Inhibitors/therapeutic use
Biomarkers
Adult
Female
Diabetic Retinopathy/diagnosis
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Fluorescein Angiography

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/IAE.0000000000003358

Cite this

Fan, W., Nittala, M. G., Wykoff, C. C., Brown, D. M., Uji, A., van Hemert, J., Fleming, A., Robertson, G., Sadda, S. R., & Ip, M. (2022). NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study. Retina, 42(3), 426-433. https://doi.org/10.1097/IAE.0000000000003358

@article{229c173cbf59494eb47f919490748706,

title = "NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study",

abstract = "PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection.METHODS: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically.RESULTS: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm2 (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm2 (P = 0.004).CONCLUSION: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.",

keywords = "Diabetic retinopathy, Retinal vascular bed area, Ultrawide field, Vascular endothelial growth factor, Receptors, Vascular Endothelial Growth Factor/therapeutic use, Prospective Studies, Intravitreal Injections, Humans, Middle Aged, Retinal Vessels/pathology, Male, Recombinant Fusion Proteins/therapeutic use, Angiogenesis Inhibitors/therapeutic use, Biomarkers, Adult, Female, Diabetic Retinopathy/diagnosis, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Fluorescein Angiography",

author = "Wenying Fan and Nittala, {Muneeswar Gupta} and Wykoff, {Charles C.} and Brown, {David M.} and Akihito Uji and {van Hemert}, Jano and Alan Fleming and Gavin Robertson and Sadda, {Srinivas R.} and Michael Ip",

note = "Funding Information: Supported by the National Natural Science Foundation of China (Grant No. 81900863). Publisher Copyright: Copyright {\textcopyright} by Ophthalmic Communications Society, Inc.",

year = "2022",

month = mar,

day = "1",

doi = "10.1097/IAE.0000000000003358",

language = "English (US)",

volume = "42",

pages = "426--433",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY

T2 - RECOVERY Study

AU - Fan, Wenying

AU - Nittala, Muneeswar Gupta

AU - Wykoff, Charles C.

AU - Brown, David M.

AU - Uji, Akihito

AU - van Hemert, Jano

AU - Fleming, Alan

AU - Robertson, Gavin

AU - Sadda, Srinivas R.

AU - Ip, Michael

PY - 2022/3/1

Y1 - 2022/3/1

N2 - PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection.METHODS: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically.RESULTS: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm2 (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm2 (P = 0.004).CONCLUSION: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.

AB - PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection.METHODS: This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically.RESULTS: For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm2 (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm2 (P = 0.004).CONCLUSION: RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.

KW - Diabetic retinopathy

KW - Retinal vascular bed area

KW - Ultrawide field

KW - Vascular endothelial growth factor

KW - Receptors, Vascular Endothelial Growth Factor/therapeutic use

KW - Prospective Studies

KW - Intravitreal Injections

KW - Humans

KW - Middle Aged

KW - Retinal Vessels/pathology

KW - Male

KW - Recombinant Fusion Proteins/therapeutic use

KW - Angiogenesis Inhibitors/therapeutic use

KW - Biomarkers

KW - Adult

KW - Female

KW - Diabetic Retinopathy/diagnosis

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Fluorescein Angiography

UR - http://www.scopus.com/inward/record.url?scp=85125009029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125009029&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000003358

DO - 10.1097/IAE.0000000000003358

M3 - Article

C2 - 34803132

AN - SCOPUS:85125009029

SN - 0275-004X

VL - 42

SP - 426

EP - 433

JO - Retina

JF - Retina

IS - 3

ER -

NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this